A
Alcista
Alcista · 25%NRXP
$3.01
Precio del escenario
$2.300
-0.311 (-13.53%)Al cierre
Loading chart…
- Máximo
- 2.840
- Apertura
- 2.830
- Precio medio ponderado por volumen
- 2.42
- Volumen
- 15.64M
- Capitalización
- 28.04M
- Mínimo
- 2.110
- Importe
- 37.80M
- EV/EBITDA, TTM
- -0.17
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. It is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal Ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 (IV ketamine) with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal depression. Its subsidiary, HOPE Therapeutics, Inc., is a healthcare delivery company that is building a network of interventional psychiatry clinics.
Análisis de IA of NRX Pharmaceuticals Inc (NRXP)
ComprarNRX Pharmaceuticals Inc is a good buy right now due to its current price of $2.49, which is significantly lower than the analyst price target of $49, indicating a potential upside of over 1,800%. Additionally, the company has received FDA Fast Track designation for its NRX-100 drug, which could expedite its market entry. However, the main risk is the current negative net income of -$16.52 million for Q2 2026, which highlights ongoing financial challenges.
Métricas de valoración
El PER previsto actual de NRX Pharmaceuticals Inc (NRXP) es 34.25, frente a su media de 5 años de 7.32.
Escenarios de precio de Alphio AI para NRXP
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Cronología de eventos
Noticias
8.510-30NewsfilterFDA Approves Preservative-Free Ketamine for NRx Pharmaceuticals
- 8.510-19Newsfilter
NRx Pharmaceuticals Successfully Manufactures Preservative-Free Ketamine
- 9.010-15Newsfilter
NRx Pharmaceuticals Receives Minor Label Change Request from FDA
9.009-16NASDAQ.COMNRx Pharmaceuticals' NRX-100 Drug Application Reclassified by FDA
8.509-14NASDAQ.COMNRx Pharmaceuticals Subsidiary Secures European Patent for ALS Treatment
Preguntas frecuentes sobre NRXP, respondidas por Alphio AI
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. It is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal Ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 (IV ketamine) with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal depression. Its subsidiary, HOPE Therapeutics, Inc., is a healthcare delivery company that is building a network of interventional psychiatry clinics. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
NRX Pharmaceuticals Inc is a good buy right now due to its current price of $2.49, which is significantly lower than the analyst price target of $49, indicating a potential upside of over 1,800%. Additionally, the company has received FDA Fast Track designation for its NRX-100 drug, which could expedite its market entry. However, the main risk is the current negative net income of -$16.52 million for Q2 2026, which highlights ongoing financial challenges.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.